High-Intensity Interval Training for Cognitive Function in Breast Cancer Patients
(CLARITY Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this research is to determine whether a 16-week high intensity interval training (HIIT) exercise program will improve brain health among women undergoing chemotherapy and also improve cardiovascular (heart) function. The names of the study interventions involved in this study are/is: * High-Intensity Interval Training (HIIT)
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the treatment High-Intensity Interval Training for Cognitive Function in Breast Cancer Patients?
Is high-intensity interval training (HIIT) safe for breast cancer patients?
Research suggests that high-intensity interval training (HIIT) is generally safe for breast cancer patients, even those undergoing chemotherapy, and can improve fitness levels. However, as with any exercise program, it is important for patients to consult with their healthcare provider before starting HIIT to ensure it is appropriate for their individual health conditions.14678
How does high-intensity interval training (HIIT) differ from other treatments for cognitive function in breast cancer patients?
High-intensity interval training (HIIT) is unique because it is a time-efficient exercise method that can improve cognitive function by increasing blood flow to the brain, potentially offering similar or better benefits compared to traditional aerobic exercises. Unlike medications, HIIT is a physical activity that can enhance brain health and cognitive abilities, making it a novel approach for cognitive rehabilitation.910111213
Research Team
Christina M Dieli-Conwright, PhD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for women over 18 with early-stage breast cancer (Stage I-III) who will undergo chemotherapy, do less than an hour of exercise a week, don't smoke, and can travel to DFCI for assessments. They must not be pregnant or have lost significant weight recently, and if they can become pregnant, they need to use birth control and take a pregnancy test.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either High-Intensity Interval Training (HIIT) or Attention Control for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants in the Attention Control group may opt into the High-Intensity Interval Training (HIIT) program after the study ends
Treatment Details
Interventions
- Attention Control (Other)
- High-Intensity Interval Training (HIIT) (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Dr. Benjamin L. Ebert
Dana-Farber Cancer Institute
Chief Executive Officer
MD from Harvard Medical School, PhD from Oxford University
Dr. Craig A. Bunnell
Dana-Farber Cancer Institute
Chief Medical Officer since 2012
MD from Harvard Medical School, MPH from Harvard School of Public Health, MBA from MIT Sloan School of Management
American Institute for Cancer Research
Collaborator